AI @ Pfizer

Pfizer launched the “Power of Knowing” video series highlighting AI integration across teams and operations to boost innovation and digital transformation, underscoring ongoing commitment to AI maturity.

• Pfizer: Pfizer Launches “Power of Knowing” Video Series

Partnership expansion with XtalPi deploying its AI-driven XFEP platform for enhanced small molecule discovery. Pfizer reported $1.2B in savings via AI-enhanced digital automation and improved drug discovery compressing timelines from years to approximately 30 days.

• Fierce Biotech: Pfizer expands XtalPi small-molecule discovery collaboration
• First Word Pharma: Pfizer finds another $1.2B in cuts by tapping AI, automation

Expanded AI use in pharmaceutical manufacturing for yield improvement and cycle time reduction. Strengthened collaboration with PostEra for generative chemistry accelerating small molecule and antibody-drug conjugate design, achieving preclinical milestones 40% faster. Introduction of a consumer-facing generative AI digital health product.

• C&EN: Pfizer doubles down on AI partnership with antibody-drug conjugate startup
• Pfizer: A New Consumer Digital Product Providing Answers You Can Trust

AI-driven drug discovery cut development times significantly, exemplified by COVID vaccine acceleration. Use of predictive models and multimodal data reduced clinical trial failure rates from 88%. Partnerships and internal hubs advanced AI integration pipeline-wide.

• Virtasant: Pfizer's AI Drug Discovery Cuts Years Off Development Time

Appointment of Berta Rodriguez-Hervas as Chief AI and Analytics Officer to steer Pfizer's AI strategy globally. Public reports discuss AI's role in expediting drug market entry processes.

• Technology Magazine: New AI Chief at Pfizer to Boost Digital Innovation

Key collaborations advanced AI-driven small molecule drug discovery with CeMM and XtalPi, enhancing predictive modeling and accelerating candidate identification. Pfizer recognized as a trusted AI/ML leader by physicians. AI also introduced in compliance and internal process automation.

• Fierce Biotech: Pfizer collab with CeMM leads to new drug discovery AI models
• Pharmaleaders: Pfizer Leads the Way for AI-Powered Compliance Copilots

Launch of 'Charlie', a customized generative AI platform for marketing content creation and compliance, significantly increasing content output (up to 5x) and speed (2-3x). AI applied in clinical trial data oversight and marketing personalization efforts.

• Digiday: With 'Charlie,' Pfizer is building a new generative AI platform for pharma marketing
• Pharmiweb: How Pfizer is Revolutionising Pharma Marketing with AI

Pfizer embraced generative AI across approximately 17 use cases, including research and marketing, and published an AI policy underscoring ethical governance.

• CIO.inc: How Gen AI Is Helping Pfizer Change Healthcare Narrative
• Pfizer: Policy Position on Artificial Intelligence

Scaling AI/ML initiatives with emphasis on collaboration to bring transformative medicines faster, confirming Pfizer’s commitment to integrating advanced analytics in R&D.

• BioSpace: Pfizer Doubles Down on AI/ML to Bring Transformative Medicines to Patients

Detailed analysis of three AI use cases at Pfizer highlighted how AI supports immediate business objectives in pharmaceutical development.

• Emerj Artificial Intelligence Research: Artificial Intelligence at Pfizer - 3 Use Cases

Pfizer reported using AI and supercomputing to accelerate vaccine and medicine development, signaling expansion beyond early trials into AI-driven discovery.

• Pfizer: Pfizer Is Using AI to Discover Breakthrough Medicines

Early AI adoption involved partnerships using IBM Watson's machine learning and NLP tools, marking Pfizer's initial steps into augmented intelligence applications.

• BioPharma Dive: Pharma and AI? Let's try augmented intelligence first